A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine
暂无分享,去创建一个
Ulrich Heininger | J. Cherry | U. Heininger | Klemens Stehr | James D. Cherry | Sabina Schmitt-Grohé | Michael Überall | Suzanne Laussucq | Thomas Eckhardt | Martin Meyer | Rita Engelhardt | Peter Christenson | S. Schmitt-Grohé | K. Stehr | P. Christenson | M. Überall | S. Laussucq | T. Eckhardt | M. Meyer | Rita Engelhardt | Martin Meyer
[1] P. Hung,et al. Clinical and serologic responses to acellular pertussis vaccine in infants and young children. , 1987, American journal of diseases of children.
[2] K. Edwards,et al. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. , 1986, American journal of diseases of children.
[3] C. Dekker,et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. , 1990, American journal of diseases of children.
[4] J. Robbins,et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. , 1997, The Journal of pediatrics.
[5] K. Edwards,et al. Differences in antibody response to whole-cell pertussis vaccines. , 1991, Pediatrics.
[6] J. Cherry,et al. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. , 1991, Developments in biological standardization.
[7] Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use--supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[8] H. Lautrop. Observations on parapertussis in Denmark, 1950-1957. , 2009, Acta pathologica et microbiologica Scandinavica.
[9] R. Belshe,et al. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. , 1988, The Journal of infectious diseases.
[10] J. Mezzatesta,et al. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. , 1990, The Journal of pediatrics.
[11] J. Cherry,et al. Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis , 1996, Infection and immunity.
[12] M. Pichichero,et al. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. , 1987, The Pediatric infectious disease journal.
[13] J. Cherry,et al. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany , 1993, The Pediatric infectious disease journal.
[14] E. Rothstein,et al. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. , 1993, A M A Journal of Diseases of Children.
[15] J. Cherry,et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany , 1995, The Pediatric infectious disease journal.
[16] M. Gahr,et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.
[17] J. Cherry,et al. Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month-old children in Japan. , 1992, American journal of diseases of children.
[18] J. Cherry,et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. , 1994, Vaccine.
[19] M. Pichichero,et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. , 1995, Pediatrics.
[20] J. Cherry,et al. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. , 1997, Developments in biological standardization.
[21] N. Guiso,et al. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species , 1993, Infection and immunity.
[22] W. Blackwelder,et al. A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.
[23] H. Hallander,et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.
[24] J. Cherry,et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. , 1994, The Pediatric infectious disease journal.
[25] J. Mezzatesta,et al. Adult immunization with acellular pertussis vaccine. , 1993, JAMA.
[26] S. Plotkin,et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants , 1991 .
[27] J. Robbins,et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. , 1997, The Pediatric infectious disease journal.
[28] S. M. Hewitt,et al. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[29] W. Blackwelder,et al. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. , 1991, American journal of diseases of children.
[30] J. Storsaeter,et al. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. , 1992, Vaccine.
[31] S. Wassilak,et al. The epidemiological situation of pertussis in the Federal Republic of Germany. , 1991, Developments in biological standardization.
[32] K. Reisinger,et al. Comparison of Acellular and Whole-Cell Pertussis-Component DTP Vaccines: A Multicenter Double-blind Study in 4- to 6-Year-Old Children , 1990 .
[33] Y. Sato,et al. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. , 1991, Developments in biological standardization.
[34] J. Cherry,et al. Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine. , 1992, Vaccine.
[35] D Greco,et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.
[36] K. Reisinger,et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. , 1992, The Pediatric infectious disease journal.
[37] S. Isomura,et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. , 1991, American journal of diseases of children.
[38] B. Watson,et al. Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants. , 1992, The Pediatric Infectious Disease Journal.
[39] J. Cherry,et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. , 1997, Developments in biological standardization.
[40] J. Cherry,et al. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children. , 1985, Developments in biological standardization.
[41] J. Cherry,et al. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. , 1986, American journal of diseases of children.
[42] C. Linnemann,et al. Bordetella parapertussis. Recent experience and a review of the literature. , 1977, American journal of diseases of children.